Global Leading Market Research Publisher QYResearch announces the release of its latest report “Human Low-Pass Whole Genome Sequencing – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032″. Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Human Low-Pass Whole Genome Sequencing market, including market size, share, demand, industry development status, and forecasts for the next few years.
The global market for Human Low-Pass Whole Genome Sequencing was estimated to be worth US120millionin2025andisprojectedtoreachUS120millionin2025andisprojectedtoreachUS280 million by 2032, growing at a CAGR of 12.5% from 2026 to 2032. For genetic researchers, population genomics scientists, and clinical diagnostics labs, the core business imperative lies in adopting human low-pass whole genome sequencing (lpWGS) that addresses the critical need for cost-effective, genome-wide variant detection (SNPs (single nucleotide polymorphisms), indels (insertions/deletions), CNVs (copy number variations)) at 0.5-5x depth coverage, combined with genotype imputation (statistical inference of ungenotyped variants using reference panels (1000 Genomes, Haplotype Reference Consortium (HRC), TOPMed)), providing an alternative to genotyping arrays for genome-wide association studies (GWAS), quantitative trait locus (QTL) mapping, polygenic risk score (PRS) calculations, population genetics, and carrier screening. lpWGS generates dense variant coverage (10-30 million variants per sample) at lower cost (US80−150persample)comparedtohigh−passWGS(30xcoverage,US80−150persample)comparedtohigh−passWGS(30xcoverage,US600-1,200). Coverage thresholds: small human low-pass WGS (≤5 Mb, ultra-low coverage 0.1-0.5x) for CNV detection, and large human low-pass WGS (>5 Mb, 0.5-5x) for SNP+indel imputation. Applications: medical (rare disease diagnosis, pharmacogenomics, cancer genomics), scientific research (population genetics, evolutionary biology, agricultural genomics), and others (personal genomics, consumer genetics).
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)】
https://www.qyresearch.com/releases/5985647/human-low-pass-whole-genome-sequencing
The Human Low-Pass Whole Genome Sequencing market is segmented as below:
BGI
Breda Genetics
Azenta Life Sciences
Thermo Fisher Scientific
Psomagen
Healgen Scientific
Agilent Technologies
Macrogen
Veritas Genetics
Centogene
Nebula Genomics
CD Genomics
Segment by Type
Large Human Low-Through Whole Genome Sequencing (>5 Mb)
Small Human Low-Through Whole Genome Sequencing (≤5 Mb)
Segment by Application
Medical
Scientific Research
Others
1. Market Drivers: Cost Reduction, GWAS Replacement, and Population Biobanks
Several powerful forces are driving the human low-pass whole genome sequencing market:
Declining sequencing costs – Illumina NovaSeq X, Element Biosciences, Ultima Genomics driving cost per genome down. Low-pass WGS (2-5x) US80−150vsgenotypingarray(US80−150vsgenotypingarray(US40-100) but offers 10x more variants, CNV detection. Genotype imputation improves accuracy.
Replacing genotyping arrays in GWAS – lpWGS + imputation provides denser variant coverage (imputed to full genome) without array design constraints, biases. Biobank-scale studies (UK Biobank, China Kadoorie Biobank (CKB), FinnGen, All of Us) using lpWGS. GWAS market shift.
Population genetics and precision medicine – Polygenic risk scores (PRS) require millions of variants for accurate prediction. lpWGS (imputed genome) enables PRS calculation from low-coverage data. Direct-to-consumer genetics (23andMe (not applicable) not WGS).
Recent market data (December 2025): According to Global Info Research analysis, large human low-pass WGS (>5 Mb coverage, 0.5-5x) dominates with approximately 80% revenue share (SNP+indel imputation, GWAS). Small human low-pass WGS (≤5 Mb, ultra-low coverage 0.1-0.5x) 20% share (CNV detection, cancer). Medical (clinical diagnostics, pharmacogenomics, predispositions) largest application (55% share). Scientific research (population genetics, GWAS) 40% share. Others 5%. North America (US, Canada) largest market (45% share) (NIH (National Institutes of Health) funded studies, biobanks). Europe (UK Biobank, FinnGen) 30% share. Asia-Pacific (China, Japan, Korea) 20% share.
2. Sequencing Coverage and Applications
| Type | Coverage Depth | Variants Detected | Imputation Accuracy | Cost per Sample | Applications | Share |
|---|---|---|---|---|---|---|
| Large (>5 Mb) | 0.5-5x | SNPs, indels, copy number (coarse) | High (r² >0.8) | US$80-150 | GWAS, PRS, population genetics | ~80% |
| Small (≤5 Mb) | 0.1-0.5x | Copy number variants (CNVs) (large) | Low (not imputed) | US$50-80 | CNV detection (cancer, developmental disorders) | ~20% |
Key parameters: Library preparation (PCR-free, low input). Sequencing platform (Illumina NovaSeq 6000/X (most common), Element AVITI, Ultima UG100). Coverage (0.5-5x, 2x most common). Imputation reference panel (1000 Genomes, HRC (Haplotype Reference Consortium), TOPMed (Trans-Omics for Precision Medicine)). Imputation accuracy (r² depends on MAF (minor allele frequency), coverage). Quality control (call rate, heterozygosity, contamination). CNV calling algorithms (CNVnator, FREEC, Canvas). Downstream analysis (PLINK, SAIGE, PRSice). Turnaround time (2-4 weeks).
Exclusive observation (Global Info Research analysis): Human low-pass WGS market is driven by large-scale biobanks (UK Biobank (650k participants) transitioning from genotyping arrays to lpWGS). China Kadoorie Biobank (CKB) (500k). FinnGen (500k). All of Us (1M) using high-pass WGS (not lp). BGI (China) leading lpWGS service provider (low-cost, high throughput). Global competition: BGI (Beijing Genomics Institute), Thermo Fisher (Ion Torrent not low-pass), Azenta, Macrogen, Veritas, Nebula, Centogene.
User case – UK Biobank (December 2025): UK Biobank (UKB) released low-pass WGS data (450,000 participants, 1-5x coverage) plus exome sequencing, genotyping array. Imputed to 1000 Genomes/HRC. Researchers used for GWAS (blood pressure, BMI, disease), PRS development. BGI provided sequencing (contract). Data cost free.
User case – polygenic risk score (PRS) (January 2026): Research lab (Europe) performs low-pass WGS (2x, NovaSeq) on 10,000 case-control for coronary artery disease (CAD). Imputed (TOPMed reference). PRS calculated (weighted sum of risk variants). Genetic risk stratification.
3. Technical Challenges
Low-coverage imputation accuracy for rare variants – R² <0.5 for variants with MAF <1%. Requires higher coverage (5-10x). Trade-off cost vs imputation quality.
CNV detection sensitivity – Ultra-low coverage (0.2x) detects large CNVs (>100kb). Small CNVs (<10kb) missed. High-pass WGS required.
Technical difficulty – batch effects and sequencing centers: Multi-center lpWGS (different flow cells, reagent lots) batch effect imputation accuracy. Uniform protocols, quality control (QC) metrics.
Technical development (October 2025): Illumina NovaSeq X (25B flow cell) reduces lpWGS cost to US$60 per sample (2x coverage). Enables biobank-scale 500k-1M samples.
4. Competitive Landscape
Key players include: BGI (China – global leader in low-pass WGS services), Breda Genetics (Italy – imputation services), Azenta Life Sciences (US – sequencing), Thermo Fisher Scientific (US – Ion Torrent, low-pass), Psomagen (US/China), Healgen Scientific (US), Agilent Technologies (US – target enrichment, not WGS), Macrogen (South Korea – sequencing), Veritas Genetics (US – consumer WGS), Centogene (Germany – rare disease), Nebula Genomics (US – consumer WGS, privacy-focused), CD Genomics (US). BGI dominates low-cost, high-volume lpWGS.
Regional dynamics: China (BGI) largest lpWGS provider (UK Biobank contract). North America (Azenta, Psomagen, Veritas, Nebula). Europe (Macrogen (division), Centogene, Breda). Asia-Pacific (BGI, Macrogen).
5. Outlook
Human low-pass whole genome sequencing market will grow at 12.5% CAGR to US280millionby2032,drivenbybiobank−scalegenomics,GWASshiftfromarraystolpWGS,andpolygenicriskscoreadoption.Technologytrends:lowercost(US280millionby2032,drivenbybiobank−scalegenomics,GWASshiftfromarraystolpWGS,andpolygenicriskscoreadoption.Technologytrends:lowercost(US50-100 per sample), improved imputation (TOPMed reference), and combined low-pass + exome (genotyping chips). Asia-Pacific growth 14-15% CAGR.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
